18.54
0.63 (3.52%)
| Previous Close | 17.91 |
| Open | 17.85 |
| Volume | 2,510,190 |
| Avg. Volume (3M) | 2,637,425 |
| Market Cap | 3,424,144,640 |
| Price / Earnings (Forward) | 50.00 |
| Price / Sales | 3.75 |
| Price / Book | 3.39 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2025 | 3,818,009 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 2,962,338 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Barclays, 331.50%) | Buy |
| Median | 58.00 (212.84%) | |
| Low | 21.00 (TD Cowen, 13.27%) | Hold |
| Average | 58.00 (212.84%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 21.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 04 Feb 2026 | 80.00 (331.50%) | Buy | 16.65 |
| 13 Nov 2025 | 90.00 (385.44%) | Buy | 31.01 | |
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (169.69%) | Buy | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (13.27%) | Hold | 19.34 |
| RBC Capital | 20 Jan 2026 | 66.00 (255.99%) | Buy | 23.42 |
| 13 Nov 2025 | 74.00 (299.14%) | Buy | 31.01 | |
| Oppenheimer | 07 Jan 2026 | 75.00 (304.53%) | Buy | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (299.14%) | Buy | 21.42 |
| 13 Nov 2025 | 75.00 (304.53%) | Buy | 31.01 | |
| Morgan Stanley | 12 Dec 2025 | 50.00 (169.69%) | Buy | 22.32 |
| UBS | 08 Dec 2025 | 48.00 (158.90%) | Buy | 26.12 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use |
| 12 Jan 2026 | Announcement | Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference |
| 17 Dec 2025 | Announcement | Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 06 Dec 2025 | Announcement | Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 |
| 27 Nov 2025 | Announcement | Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade |
| 13 Nov 2025 | Announcement | Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia |
| 12 Nov 2025 | Announcement | Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |